维普期刊资源整合服务平台（V6.5）

47篇 您的检索式：作者名="Blagden"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates 显示文摘	Blagden N deMatas M Gavan P T	2007	Advanced Drug Delivery Reviews2007，59，7：	1
2	Hedgehog signaling is required for maintenance of Myf-5 and MyoD expression and timely terminal differentiaion in zebrafish adaxial myogenesis显示文摘	COUTELLE O BLAGDEN C S HAMPSON R	2001	Developmental Biology2001，236，1：	1
3	Preparation of hydrocortisone nano suspension through a bottom up nanoprecipitation technique u- sing microfluidic reactors显示文摘	All HS York P Blagden N	2009	International Journal of Pharma-ceutics2009，375，12：	1
4	Preparation of hydrocortisone nano- suspension through a bottom-up nanoprecipitation technique using microfluidic reactors 显示文摘	Ali HSM York P Blagden N	2009	lnt J Pharm2009，375，12：	1
5	Notochord induction of zebrafish slow muscle mediated by sonic hedgehog显示文摘	BLAGDEN C S CURRIE P D INGHAM P W	1997	Genes & Development1997，11，17：	1
6	Effects of active and passive rumination and distraction:A pilot replication with anxious mood显示文摘	Blagden J C Craske M G		0，，10：	1
7	Phase Ⅰ first-inhuman study of the Polo-like kinase-1 selective inhibitor,GSK461364,in patients with advanced solid tumors显示文摘	Blagden S Olmos D Sharma R		0，，15：	1
8	Crystal engineering of polymorph appearance, the case of sulphathiazole显示文摘	Blagden N		0，，1：	1
9	Reduction of Levels of Vola- tile Components Associated with the ' Beany' Flavor in Soymilk by Lactobacilli and Streptococci 显示文摘	Blagden T D Gilliland S E	2005	Journal of Food Science2005，70，3：	1
10	Current directions in co-crystal growth显示文摘	Blagden N Berry D J Parkin A	2008	New J Chem2008，32，：	1
11	Making sense of antisense显示文摘	Vidal L Blagden S Attard G de Bono J	2005	Eur J Cancer2005，41，18：	1
12	Runx1 prevents wasting,myofibrillar disorganization,and autophagy of skeletal muscle显示文摘	Xiaoxia Wang Chris Blagden Jihua Fan	2005	Genes Dev2005，19，14：	1
13	Ordered aggregation of benzamide crystal induced using a 'Motif Capper' additive显示文摘	Blagden N Song M Davey R J	2005	Crystal Growth and Design2005，5，2：	1
14	Cryslal engineering of polymorph appear ance: the case of s ulphathiazole显示文摘	Blagden N	2001	Powder Technolo gy2001，121，1：	1
15	Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates 显示文摘	Blagden N De M M Gavan P T	2007	Adv Drug Deliv Rev2007，59，7：	1
16	Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates显示文摘	Blagden N de Matas M Gavan P T	2007	Adv Drug Deliv Rev2007，59，7：	1
17	Nucleation control in solution mediated polymorphic phase transformations:the case of 2,6-dihydroxybenzoic acid显示文摘	Davey R J Blagden N Righini S Alison H Ferrari E S		0，，：	1
18	Harnessing Pandemonium:The Clinical Im- plications of Tumor Heterogeneity in Ovarian Cancer 显示文摘	Blagden SP	2015	Front Oneol2015，5，：	1
19	A phase Ib study of pertuzumab, a re- combinant humanized antibody to HER2,anddocetaxel in patients with advanced solid tumours 显示文摘	G Attard J Kitzen SP Blagden	2007	British Journal of Cancer2007，97，：	1
20	Targeting cell cyclekinases and kineains in anlicancer drug development 显示文摘	YapTA Molife LR Blagden SP	2007	Expert Opin Drug Discov2007，2，53：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示